Journal: BMC Microbiology

Article Title: Pathogenic signatures and therapeutic evaluation of emergent MPXV Clade Ib in low-susceptibility and immunocompromised mouse models

doi: 10.1186/s12866-026-05273-4

Figure Lengend Snippet: Validation of AGB6, STAT1 −/− , and C57BL/6 Mice for MPXV Clade Ib Drug Evaluation. a : Mice were infected with MPXV Clade Ib via intranasal administration at a dose of 2 × 10 5 pfu/50 µl ( n = 3–5 mice per group). Tecovirimat (10 mg/kg) was administered intragastrically once daily starting from the day of infection, while the control group received an equal volume of vehicle alone. Mouse status was monitored daily and body weight was recorded post-infection. Mice were euthanized at appropriate time points for subsequent assays. b , d , f : Changes in mouse body weight post-viral infection (expressed as the percentage loss relative to initial body weight) (analyzed by multiple t test). c , e , g : Viral loads in mouse lung tissues, with titers expressed as PFU equivalents/g of tissue. h : Hematoxylin-eosin (HE) staining of mouse lung tissues. Orange arrows indicate bronchial necrosis; yellow arrows indicate peribronchial epithelioid cell hyperplasia; blue arrows indicate fibrosis; red arrows indicate inflammatory cell infiltration; green arrows indicate necrotic tissue debris and inflammatory cells in the bronchial lumen; gray arrows indicate pulmonary edema; cyan arrows indicate hemorrhage; black arrows indicate alveolar wall thickening. The right panel (bars = 1000 μm) shows the magnified view of the boxed area in the left panel (bars = 100 μm). i : Immunohistochemistry (IHC) staining of MPXV A29 protein in mouse lung tissues on day 7 post-infection. The right panel (bars = 100 μm) shows the magnified view of the dashed box area in the left panel (bars = 1000 μm). j , k , l : Quantitative analysis of viral protein-positive signals in Fig. i was performed using the color deconvolution method in Image J software

Article Snippet: Tecovirimat was obtained from MedChemExpress (MCE: HY-14805).

Techniques: Biomarker Discovery, Infection, Control, Staining, Immunohistochemistry, Software